Episode 108: Colorectal Cancer Series, Pt. 10...

This week, we begin our discussion about treatment of multiple myeloma, focusing on the first-line setting. Once again, a lot has changed in this space over the last few years, most notably the standards of care (now quadruplet regimens instead of triplet regimens!). We break dow ...  Show more

This week, we introduce a new episode for our myeloma series, this time focusing on risk stratification and response criteria. The initial workup and surveillance labs are expansive, but all of the studies we do have a purpose. Many present-day studies also use “minimal residual ...  Show more

Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024.

In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel A ...

In the first episode of the ID:IOTS podcast Callum and Jame talk for longer than intended about everyone's favourite Gram positive coccus, Staphylococcus aureus. Audience survey: Tell us how rubbish we are here! Support the showWe are currently seeking more detailed feedback, ple ...  Show more

Join Jame and Callum as they discuss this paper which examines where these new antibiotics are going, and why they aren't widely available.Notes for this episode here Support the showWe are currently seeking more detailed feedback, please help us improve the podcast by giving you ...  Show more

Join Lebaron (Lee) Agostini and Connor Wander in our FIRST VIDEO episode! This episode is all about Cancer Biology. Lee studies experimental cancer therapies for pancreatic cancer. New cancer therapies called combination or synergystic cancer therapies use multiple drug types to ...  Show more